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Summary 
 
 
Collagen VI is the main extracellular matrix (ECM) protein synthesized and 
secreted mainly by fibroblasts that forms a structurally network of 
microfilaments.  
Collagen VI binds several cell surface receptors and ECM components, 
suggesting that collagen VI is an important mechanical link between muscle cells 
and surrounding ECM. [1] 
Mutations related to COL6A1, COL6A2 and COL6A3 genes encoding for the three 
main collagen VI chains, cause the collagen VI-related myopathy, a specific 
subtype of congenital muscular dystrophy (CMD). 
In particular Ullrich congenital muscular dystrophy (UCMD) is a severe form 
characterized by progressive muscle wasting leading to loss of ambulation 
around ten years of age and respiratory problems in late childhood or young 
adulthood. 
Bethlem Miopathy (BM) is a mild-form characterized by a slow course usually 
without respiratory symptoms where around 50% of patients lose ambulation in 
the fifth decade. [2] 
Being the genetic test aimed to find mutations in COL6A genes expensive and 
time consuming mainly because the large size of the three genes,  (106 coding 
exons in total [2]) the diagnosis of collagen VI-related myopathies is based on 
the clinical signs assessment coupled to the muscular biopsy which is useful to 
highlight any dystrophic or myopathic changes in the muscle fibers of the 
patient. 
The aim of the present work has been to identify a panel of miRNAs significantly 
dysregulated in col6a1-/- mice, the animal model of Bethlem myopathy and 
Ullrich congenital muscular dystrophy.  
miRNAs represent an ideal biomarker because they are easy to detect, well 
preserved in serum and non invasive. 
The findings of this work can be translated, in a further step, in a cohort of 
affected patients in order to become a powerful tool for the diagnosis and the 
follow-up of collagen VI-related myopathy. 
 
Research projects aimed to link the differential miRNA expression to pathological 
conditions are increasing and this suggests how miRNAs could be used as 
powerful tool to track disease related changes on a large scale in the 
forthcoming years.   
In order to identify differentially expressed miRNAs in knock-out col6a1-/- (KO) 
mice serum, a miRNAs expression profiling analysis by SYBR Green-based real-
time PCR of 752 miRNAs in 5 col6a1+/+(WT) and 6 col6a1-/- has been performed.  
Fifty one (6.5%) of the 333 miRNAs expressed in col6a1-/- mice serum, showed a 
significant dysregulation between col6a1-/- and WT mice serum. 
The statistical analysis revealed 17/51 miRNAs up-regulated and 34/51 down-
regulated.  
To further characterized the dysregulated miRNAs we checked their involvement 
in disease related pathways coupled with literature analysis. 
These analyses showed that mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-7c-
5p and mmu-let-7b-5p are up-regulated in col6a1-/- mice serum, whereas mmu-
miR-29b-3p and mmu-miR-29a-3p are downregulated of. These observations 
are quite interesting because these miRNAs could play an important role in the 
collagen VI-related myopathies linking genes involved in essential signalling 
pathway for skeletal muscle cells development, differentiation or coding for ECM 
proteins. 
In particular miRNAs targets interfere with ERBb, MAPK, PIK3/Akt, mTOR, ECM-
receptors, actin cytoskeleton, focal adhesion and calcium signalling. 
In conclusion, this project has identified 6 dysregulated microRNAs (mmu-miR-
195a-5p, mmu-miR-26a-5p, mmu-let-7c-5p, mmu-let-7b-5p, mmu-miR-29b-3p 
and mmu-miR-29a-3p) that could be used in future studies as biomarkers and 
possibly as a tool for the diagnosis and the follow-up of collagen VI-related 
myopathies.   
Further analyses in larger cohorts of BM and UCMD patients are needed in order 
to validate the data obtained in mice models.  
 
 
 
Riassunto 
 
Il collagene VI, sintetizzato e secreto principalmente da fibroblasti, è uno dei 
maggiori costituenti della matrice extracellulare (ECM) ove forma una fitta rete 
di microfilamenti. 
Questa proteina prende contatto con diversi recettori localizzati sulla membrana 
cellulare e allo stesso tempo con altri componenti della matrice extracellulare 
indicando che, probabilmente, il collagene VI ha un ruolo importante nella 
trasmissione dei segnali tra l’interno e l’esterno della cellula oltre che una 
funzione puramente strutturale.[1] 
Mutazioni legate ai geni COL6A1, COL6A2 e COL6A3, codificanti per le catene 
principali del collagene VI, causano la distrofia muscolare congenita di Ullrich 
(UCMD) e la variante mite, miopatia di Bethlem (BM). 
La UCMD è una forma severa di distrofia muscolare caratterizzata da un deficit di 
forza progressivo che porta, nella maggior parte dei pazienti, alla perdita della 
deambulazione attorno al decimo anno di vita e a problemi respiratori nella tarda 
adolescenza o all’inizio dell’età adulta. 
La BM è una forma di miopatia meno severa rispetto alla UCMD caratterizzata da 
un decorso più lento e dalla assenza di insufficienza respiratoria. Circa il 50% dei 
pazienti con BM perde la deambulazione dopo la quinta decade. [2]  
La ricerca di mutazioni nei geni COL6A1, COL6A2 e COL6A3 è una procedura 
costosa e complessa (la sequenza codificante dei tre geni è pari a 106 esoni 
[2]), e la diagnosi di collagenopatia è spesso basata sulla presentazione clinica e 
sulle caratteristiche della biopsia muscolare.  
La biopsia muscolare è una procedura invasiva di elevato costo.  
Lo scopo di questo studio è stato quello di identificare dei microRNA (miRNA) 
significativamente disregolati nel siero del topo col6a1-/-, modello animale di 
collagenopatia, per individuare un pannello di biomarcatori da poter studiare, in 
una fase successiva, in pazienti affetti da UCMD e BM.   
I miRNA sono dei biomarcatori ideali, non invasivi, in quanto facili da dosare e 
stabili nel siero.  
L’identificazione di biomarcatori non invasivi rappresenterà un importante  
strumento per la diagnosi e il follow-up delle collagenopatie. 
Al fine di identificare miRNA differenzialmente espressi nel siero del topo col6a1-
/- (KO) e col6a+/+ (WT), sono stati analizzati 752 diversi miRNA in 11 campioni 
(rispettivamente n=5 WT e n=6 KO). 
333 miRNA sono risultati espressi nel siero dei topi KO ed il 6,5%, 51 miRNA, 
sono risultati significativamente disregolati nel siero dei topi WT rispetto a quello 
dei KO (17/51 miRNAs up-regolati e 34/51 down-regolati). 
I miRNA disregolati  sono stati caratterizzati avvalendosi di specifiche analisi di 
pathway accoppiate ai dati trovati in letteratura.  
I miRNAs: mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-7c-5p, mmu-let-7b-
5p sono risultati up-regulati nel siero dei topi Col6a1-/- mentre  mmu-miR-29b-
3p e mmu-miR-29a-3p down-regulati.  
Questi miRNAs potrebbero giocare un ruolo importante nella patogenesi delle 
collagenopatie in quanto legano geni coinvolti in importanti pathway molecolari 
necessarie ad un corretto sviluppo e differenziamento della cellula muscolare, e 
a pathway coinvolti nella produzione di proteine della ECM. 
I pathway interessati sono stati: ERBb, MAPK, PIK3/Akt, mTOR, ECM-receptors, 
actin cytoskeleton, focal adhesion e calcium signalling. 
In conclusione in questo studio sono stati identificati e selezionati 6 miRNA 
significativamente disregolati (mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-
7c-5p, mmu-let-7b-5p, mmu-miR-29b-3p and mmu-miR-29a-3p) nel modello 
murino di topo knock down per il collagene VI.   
Questi miRNA sono candidati alla caratterizzazione nel siero di pazienti con UCM 
e BM e potrebbero diventare ottimi biomarcatori non invasivi per la diagnosi ed il 
follow-up dei pazienti. 
Ulteriori studi verranno effettuati in ampie coorti di pazienti affetti al per 
confermare questi dati preliminari. 
 
 
 
 
 
 
 
1.Introduction 
 
1.1 Muscular dystrophies 
Muscular dystrophies (MDs) are a clinically and genetically heterogeneous group 
of diseases sharing clinical signs and symptoms, in particular a variable degree 
of progressive muscle weakness that affects limb, facials and axial muscles 
associated to dystrophic pathological features observed in muscle biopsy [3]. 
The age of onset, severity and progression rate is variable between patients and 
it depends on the type of MD [4]. 
Dystrophic muscle is usually characterized by alteration in muscle fibers size 
with infiltration of connective and fatty tissues, and centrally located nuclei.  
Often, the cell membrane is fragile and subjects to extensive damage leading to 
necrosis and muscle wasting [5]. 
Nowadays, a better understanding of the molecular pathway underlying 
muscular dystrophies, combined to new treatment approaches, changed both 
the natural history and life of the patients in terms of quality and lifespan. 
Several studies identified some of the mutant genes leading to MD disorders and 
allowing the development of new clinical trials.[6, 7] 
 
 
1.1.2 Classification and main clinical manifestations 
MDs are classified based on clinical and genetic features. 
DMD is the main type of MD affecting 1 per 3600-6000 live male births; other 
muscular disorders are the facioscapulohumeral muscular dystrophy (FSHD) (1 
per 20000 live birth), congenital muscular dystrophy (CMD) (from 1 per 21500 
to 1 per 16000 live birth) and the limb-girdle muscular dystrophy (LGMD) (0.8 
per 100000 live birth). 
MD types differs among them in terms of onset age, pattern of inheritance 
weakness distribution, rate of progression, grade of hypertrophy and, in 
some cases by serum levels of sarcoplasmic enzymes like creatine kinase 
(CK).[8, 9] 
Generally, the onset of clinical signs varies, ranging from birth or childhood to 
adulthood and the most consistent finding is the weakness of the skeletal 
muscles often associated with either muscle atrophy, hypertrophy, or both.  
The progression of the disease is variable and related to the gene mutations. 
Cardiac involvement and respiratory impairment are common features in many 
MDs (with different grade of severity), while a functional or structural brain 
involvement occurs just in a few types of congenital muscular dystrophies and 
rarely in limb girdle muscular dystrophy variants.[4] 
 
 
 
 
 
Type Inheritance Gene Protein
Duchenne or Becker muscular 
dystrophy
X-R DMD Dystrophin
Limb girdle muscular dystrophy
Type 1A AD MYOT Myotilin
Type 1B AD LMNA Lamin A/C
Type 1C AD CAV3 Caveolin-3
Type 1D AD DNAJB6 Co-chaperone DNAJB6
Type 1E AD DES Desmin
Type 1F AD Unknown Unknown
Type 1G AD Unknown Unknown
Type 1H AD Unknown Unknown
Type 2A AR CAPN3 Calpain-3
Type 2B AR DYSF Dysferlin
Type 2C AR SGCG γ-sarcoglycan
Type 2D AR SGCA α-sarcoglycan
Type 2E AR SGCB β-sarcoglycan
Type 2F AR SGCD δ-sarcoglycan
Type 2G AR TCAP Titin cap (telethonin)
Type 2H AR TRIM32 Tripartite motif-containing 32 (ubiquitin ligase)
Type 2I AR FKRP Fukutin-related protein
Type 2J AR TTN Titin
Type 2K AR POMT1 Protein-1-O-mannosyl-transferase 1
Type 2L AR ANO5 Anoctamin 5
Type 2M AR FKTN Fukutin
Type 2N AR POMT2 Protein-O-mannosyl-transferase 2
Type 2O AR POMGNT1 Protein-O-linked mannose β 1,2-N-
Type 2P AR DAG1 Dystrophin-associated glycoprotein 1
Type 2Q AR PLEC1 Plectin 1
Facioscapulohumeral muscular 
dystrophy
Type 1 AD Unknown DUX4 and chromatin rearrangement
Type 2 AD Unknown SMCHD1
Emery-Dreifuss muscular dystrophy
X-linked type 1 X-R EMD Emerin
X-linked type 2 X-R FHL1 Four and a half LIM domain 1
Autosomal 
dominant
AD LMNA Lamin A/C
Autosomal 
recessive
AR LMNA Lamin A/C
With nesprin-1 
defect
AD SYNE1 Spectrin repeat containing, nuclear envelope 1 
(nesprin-1)
With nesprin-2 
defect
AD SYNE2 Spectrin repeat containing, nuclear envelope 2 
(nesprin-2)
  
 
Congenital muscular dystrophy with 
merosin deficiency (MDC1A)
AR LAMA2 Laminin α2 chain of merosin
Congenital muscular dystrophy AR Unknown Unknown
Congenital muscular dystrophy and 
abnormal glycosylation of 
dystroglycan (MDC1C)
AR FKRP Fukutin-related protein
Congenital muscular dystrophy and 
abnormal glycosylation of 
dystroglycan (MDC1D)
AR LARGE Like-glycosyl transferase
Fukuyama congenital muscular 
dystrophy
AR FCMD Fukutin
Walker–Warburg syndrome
With fukutin 
defect
AR FCMD Fukutin
With protein-O-
mannosyl-
transferase 1 
defect
AR POMT1 Protein-1-O-mannosyl-transferase 1
With protein-O-
mannosyl-
transferase 2 
defect
AR POMT2 Protein-O-mannosyl-transferase 2
With protein-O-
linked mannose 
β 1,2-N-
aminyltransferas
e 1 defect
AR POMGNT1 Protein-O-linked mannose β 1,2-N-
aminyltransferase 1
With fukutin-
related protein 
defect
AR FKRP Fukutin-related protein
Muscle-eye-brain disease
With protein-O-
linked mannose 
β 1,2-N-
aminyltransferas
e 1 defect
AR POMGNT1 Protein-O-linked mannose β 1,2-N-
aminyltransferase 1
With fukutin-
related protein 
defect
AR FKRP Fukutin-related protein
With protein-O-
mannosyl-
transferase 2 
defect
AR POMT2 Protein-O-mannosyl-transferase 2
Congenital muscular dystrophy due 
to glycosylation disorder
AR DPM2 Dolichyl-phosphate mannosyltransferase 
polypeptide 2
Congenital muscular dystrophy due 
to glycosylation disorder
AR DPM3 Dolichyl-phosphate mannosyltransferase 
polypeptide 3
Congenital muscular dystrophy with 
mitochondrial structural 
abnormalities
mtDNA CHKB Choline kinase
Congenital muscular dystrophy with 
rigid spine syndrome
AR SEPN1 Selenoprotein N1
Ullrich syndrome
With collagen 
type VI subunit 
α1 defect
AR COL6A1 Collagen type VI, subunit α1
With collagen 
type VI subunit 
α2 defect
AR COL6A2 Collagen type VI, subunit α2
With collagen 
type VI subunit 
α3 defect
AR COL6A3 Collagen type VI, subunit α3
Congenital muscular dystrophy with 
integrin α7 defect
AR ITGA7 Integrin α7
Congenital muscular dystrophy with 
integrin α9 defect
AR ITGA9 Integrin α9
Muscular dystrophy with generalised 
lipodystrophy
AR PTRF Polymerase I and transcript release factor (cavin-
1)
Oculopharyngeal muscular dystrophy AD or AR PABPN1 Polyadenylate binding protein nuclear 1
Imagine 1. Classification of muscular dystrophies. X-R=X-linked recessive. OMIM=Online 
Mendelian Inheritance in Man. AD=autosomal dominant. AR=autosomal recessive. (Mercuri, E. 
and F. Muntoni, Muscular dystrophies. Lancet, 2013.) 
 
1.1.3 Diagnosis 
In order to ameliorate the life quality and disease history an early diagnosis is 
essential.  
Usually it is made by an assessment of clinical signs and symptoms coupled with 
genetics and biochemical analyses aimed to characterize the MD type. 
Muscle biopsy is usually mandatory to assess the diagnosis and gives important 
information regarding the fibers morphology, the presence/absence of 
inflammatory infiltrates or fatty tissue and it is essential to exclude overlapping 
features observed during the diagnosis assessment in many MD patients. 
As mentioned before, serum creatinine kinase (CK) concentrations are often 
higher than normal values, but do not indicate a specific MD [4]. 
 
 
 
 
 
 
1.2 Congenital muscular dystrophies 
 
Congenital muscular dystrophies (CMDs) are a group of hereditary myopathies 
clinically and genetically heterogeneous mainly characterized by autosomal 
recessive inheritance having variable clinical course and presenting sometimes 
central nervous system (CNS) and ocular symptoms. 
In general CMDs biopsies highlight variability in the size of muscle fibers which 
show internal nuclei, especially during the early stages of the disease, and 
infiltrations of adipose tissue. 
CMDs classification has been proposed and continuously updated, but in general 
they are divided into 5 subtypes based on the phenotypic and genotypic features 
[10]. 
Imagine 2. Immunostaining of collagen VI in skeletal muscle showing that collagen VI is absent 
in basement membrane muscle fibers of a UCMD patient (right) compared to a normal control 
(left). (Imagine taken from Lampe A K , and Bushby K M D J Med Genet 2005;42:673-685) 
 
 Forms of CMDs caused by mutations in genes encoding for basal lamina 
structural proteins or extracellular matrix (ECM) proteins.  
It has been reported CMDs variants due to mutations in COL6A1, COL6A2 
and COL6A3 genes such as the Ullrich congenithal muscular dystropy 
(UCMD) and the Bethlem myopathy (BM) or CMD variants caused by 
mutations occuring in laminin α-2 (LAMA2), integrin α-7 (ITGA7) and 
integrin α-9 (ITGA9) genes 
 CMD forms could be linked to genetic mutations in glycosyltransferases 
that affect the glycosilation of α-dystroglycan (ADG). Several genes 
involved in this pathway could lead to secondary dystroglycanopathies 
such as Fukuyama CMD, muscle-eye-brain disease (MEB), Walker-
Warburg syndrome, CMD variant 1C (MDC1C) and variant 1D (MDC1D).  
 Other forms caused by deficiency of nuclear envelope proteins (LMNA and 
nesprin) or other proteins with unknown function localized in the 
endoplasmic reticulum and, finally, CMDs with mitochondrial structural 
abnormalities (CMDmt) [11]. 
 
 
 
 
 
 
 
 
 
 
1.3 Collagen VI 
Collagen VI is the main extracellular matrix (ECM) protein forming a structurally 
network of beaded microfilaments. 
It is synthesized and secreted by fibroblasts and muscle cells.  
Collagen VI is mainly expressed in connective tissues [12] and is composed by 
three major chains: α1(VI), α2(VI) and α3(VI), encoded respectively by COL6A1, 
COL6A2 and COL6A3 genes. 
The α1 (VI) and α2 (VI) chains are around 1000 amino acids long and 140 kDa, 
while α3 (VI) chain is 250-300 kDa and it is composed from  a sequence of 
2500-3100 amino acids. [13, 14] The three “minor” chains α4, α5 and α6 are 
highly homologous to the α3 chain [15, 16] . 
Structurally all collagen VI chains consist of a short triple-helical region whereas 
the N- and C-terminal of the protein present globular structures. These globular 
features are largely formed by Von Willebrand factor A (VWA) consisting of 
around 200 amino acid residues that are assuming a Rossmann folding with a  
core β sheet conformation surrounded by amphipathic α helices. VWAs are 
present in many proteins like integrins, matrilins and collagens[17, 18]  and 
often contain an highly conserved metal-ion-dependent adhesion site (MIDAS). 
Usually this motif is  involved in ligand binding [19]. 
In collagen VI, the N terminal of  α1 and α2 chains present one VWA domain 
each, while α3, α4, α5 and α6 chains show from seven to ten VWA domains at 
the N-terminal of the protein 
In the C terminal region, all the chains are composed by two VWA domains, 
except the α5 chain which has three VWA domains.   
The assembling of collagen subunits takes place in several steps. 
At the beginning α1, α2 and α3 chains form triple helical monomers that are 
going to be arranged into disulfide-bonded antiparallel dimers. 
Subsequently, the dimers are aligned and assume the tertiary protein structure 
of 145 nm tetramers stabilized by disulfide bonds. 
After secretion, collagen microfibrils assume a “beads-on-a-string” appearance 
due to the tetramers head-to-head interaction.[12] 
Secreted collagen VI consists of at least 60 tetramer units up to 6 μm in length. 
[20] 
Collagen VI is involved in interactions with cell surface receptors.  
In particular, through the triple helical region and the VWA domains, collagen VI 
binds several cell surface receptors and especially ECM components such as 
integrins, fibrillar collagens, basal lamina (type IV) collagen, decorin, byglycan 
and fibronectin [21, 22]. 
These interactions with several ECM components suggest that collagen VI plays 
an important mechanical role between muscle cells and surrounding ECM 
components [1].  
 
 
 
 
 
The human COL6A1 and COL6A2 genes are clustering in the most distal part of 
chromosome 21 while COL6A3 gene is in chromosome 2 [20]. 
 
Imagine 3. Domains and assembly of collagen VI protein. (Imagine taken from 
Bönnemann, C. G. (2011) The collagen VI-related myopathies: muscle meets its 
matrix Nat. Rev. Neurol. doi:10.1038/nrneurol.2011.81) 
 
  
 
1.3.2 Collagen VI gene mutation and related myopathies 
Mutations affecting the three major collagen VI genes COL6A1, COL6A2 and 
COL6A3 have been associated to the congenital muscular dystrophy type Ullrich 
(UCMD) showing a severe phenotype, with the mild-phenotype Bethlem 
myopathy (BM) and with the recently identified congenital myosclerosis. [23, 24]  
The disease-causing mutations are often point nonsense mutations usually 
inherited with recessive mode, leading to premature termination codons (PTCs) 
or missense mutations in glycine residues in the triple helical domains resulting 
in a block of the triple-helix formation. [23, 24] 
These type of mutations usually arise as in-frame exon skipping pattern. 
Dominant de-novo mutations affecting in particular exon 16 of COL6A3 and exon 
14 of COL6A1 lead to UCMD or BM phenotypes respectively, even if a genotype-
phenotype for the collagen VI myopathies is difficult to identify [2].  
UCMD is often linked to mutations in COL6A1, COL6A2 and COL6A3 genes and 
patients’ phenotype is characterized by hypotonia and muscle weakness in the 
neonatal period often associated with kyphosis of the spine, dislocation of the 
hips and proximal contractures. 
Most of patients show rounded face and prominent ears and their skin could 
show follicular hyperkeratosis and keloid formation. 
Maximum motor capacity is variable across patients and some of them are 
unable to be ambulant. 
Respiratory insufficiency appears in the first or second decade. 
Bethlem myopathy is characterized by mild-progressive muscle weakness (more 
proximal than distal), with contractures occuring in finger flexors, elbow and 
ankle.  
Gene Locus
COL6A1 Human 21q22.3
Mouse chromosome 10
COL6A2 Human 21q22.3
Mouse chromosome 10
COL6A3 Human 2q37
Mouse chromosome1
Imagine 4. The loci of the genes coding for the three polypeptide chains of 
collagen VI protein. 
A low proportion of BM patients lose ambulation in adult life and rarely in 
adolescence. However they are not affected by cardiac and respiratory clinical 
problems.  
In the past BM has been associated to dominant mutations, whereas UCMD has 
been linked to recessive mutations, but nowadays this distinction is not 
consistent. [25] 
Congenital myosclerosis is a rare disorder linked to an homozygous mutation of 
the COL6A2 gene resulting in reduced expression of collagen VI wherein patients 
muscles highlight a “woody” consistency. [24] 
 
1.3.3 Diagnosis 
Due to the lack of specific clinical and laboratory findings, the diagnosis of 
collagen VI-related myopathies should be made performing genetic tests aimed 
to analyse the collagen VI genes.  
These analysis are expensive and time consuming due to the large genes size 
composed by 106 coding exons.[2]  
In general diagnosis is achieved combining clinical features and muscle biopsy 
variations, even if a loss of collagen VI could be observed also in skin fibroblasts.   
In BM patients, collagen VI immunostaining is almost normal or slightly reduced 
in muscle. Also a secondary reduction of laminin β1 staining expression could be 
observed in older patients. 
In UCMD patients, collagen VI immunostaining highlight a lack or strong 
reduction of collagen VI in endomysium and basal lamina.[26] 
 
 
 
1.4 microRNAs 
MicroRNAs (miRNAs) are non coding RNAs (ncRNAs) long at least 22 nucleotides 
that are able to bind specific mRNA targets and consequently regulate their gene 
expression through mRNA target degradation or, in general, inhibiting the 
translation.  
Human genome encodes for around 1.000 miRNAs and each microRNA can bind 
multiple genes (hundreds).  
Every single microRNA can therefore act in different molecular pathways, thus it 
can be of great biological interest to make predictions about the impact that the 
miRNAs-mRNA link may have on the disease related mechanisms. Under this 
perspective microRNA expression changes due to collagen VI related myopathies 
may also shed some light on disease pathogenesis. [27]  
 
1.4.1 miRNA biogenesis and mechanism of action 
The first miRNA biogenesis step occurs in the nucleus with the production of a 
primary transcript of the miRNA (pri-miRNA) composed by two or more hairpins 
encompassing the sequence of the mature miRNA in their stem. 
Subsequently, the pri-miRNA is recognized and bound by the enzymes Drosha 
and DGCR8 that create one or more hairpins about 70 nucleotides long, called 
precursor miRNAs (pre-miRNAs), which will be exported to the cytoplasm by the 
enzyme Exportin 5 (XPO5). 
RNaseIII enzyme Dicer recognizes the pre-miRNA  and  removes the hairpin 
loop, generating a double-strand RNA molecule (dsRNA) long about 20 bp .  
Finally one strand of the dsRNA is incorporated in the RNA-inducing silencing 
complex (RISC) composed by the Argonaute protein 2 (AGO-2) and the GW182.  
Once assembled, RISC binds the 3 'UTR of a gene having a sequence 
complementary to the miRNA.  
This binding leads to target gene cleavage mediated by AGO-2, if there is an 
high homology between miRNA and target gene, or may lead to degradation due 
to the mRNA deadenylation.  
In general, a good affinity between the two molecules requires a  6-8 continuous 
base pairing between target mRNA and miRNA seed region (formed by 
nucleotides in position 1 to 8 of the mature miRNA).[28] 
 
  
 
 
 
 
 
 
 
1.4.2 microRNA as potential biomarkers for neuromuscular 
disorders 
Imagine 5. MicroRNA biogenesis and their repressing activity. (Imagine taken from Julia 
Winter, Stephanie Jung, Sarina Keller, Richard I. Gregory & Sven Diederichs – 2009  Nature Cell 
Biology 11, 228 – 234,) 
A biomarker is a measurable biological element that is able to reveal the 
presence of pathological status and possibly is variable in response to 
pharmacological treatments. 
A valid biomarker would also be detectable in early disease stages, be non-
invasive and its detection should be fast and relatively cheap. 
In this sense microRNAs are a great example of candidate biomarkers and 
nowadays the research projects aimed to study the differential miRNA 
expression linked to pathological conditions are increasing. 
Cell-free nucleic acids such as miRNAs can be detected in different body tissues 
and fluids like blood, where they are stably thanks to the association with the 
RISC complex or because they are included in microvescicles or exosomes.  
Changes of miRNA expression profiles in neuromuscular diseases could be an 
useful biomarker for disorders like collagen VI-related diseases which require 
cheaper, faster and less invasive methods of diagnosis.[29]  
To date, several studies have been focused to the identification of miRNAs 
dysregulated in skeletal muscle disorders. 
Eisenberg and colleagues profiled miRNAs in muscle samples of human patients 
with primary muscle disorders and found a set of miRNAs commonly 
dysregulated in patients.[30]  
Previous works have shown that members of miR-1/206 and miR-133a/133b 
miRNA families are specifically expressed in both skeletal and cardiac muscle.  
These miRNAs originate from the same transcripts on three separate 
chromosomes and the myogenic transcription factors SRF, MEF2 and MyoD 
regulate and control the expression of miR-1 and miR-133a in muscles. [31] 
Cacchiarelli and colleagues showed that microRNAs, specifically expressed in 
muscle cells, were released into the blood of DMD patients as a consequence of 
muscle degeneration and their amount correlates with the severity of the 
disease. 
In particular miR-1, miR-133 and miR-206 were highly abundant in the 
bloodstream of DMD patients. 
In the same work, the results obtained from patients have been confirmed in the 
animal model of DMD, the mdx mouse.  
In particular in 2 month-old animals, both miR-1 and miR-206 were more 
abundant in the serum of mdx mice in comparison to WT controls.[32] 
Zaharieva and colleagues showed higher amounts of miR-1, miR-133a and miR-
133b levels in serum of DMD patients during the early stages of the disease and 
a consequently reduction of their levels related to the disease progression. 
They have hypothesized that lower amounts of circulating miRNAs might reflects 
the loss of muscle fibres replaced by connective and adipose tissues.[33] 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.Aim  
 
Nowadays the diagnosis of collagen VI-related myopathies and congenital 
muscular dystrophies in general is based on clinical signs assessment coupled to 
genetic analysis and muscular biopsy, which is useful to highlight any dystrophic 
changes in patients’muscles.  
miRNAs have been defined as ideal biomarkers and are also stable in serum.  My 
final goal in this project  was the identification of a panel of candidate miRNAs 
significantly dysregulated in the animal model of Bethlem myopathy and Ullrich 
congenital muscular dystrophy that may become candidate to be studied in 
affected patients.  
These investigations could shed new light for the diagnosis and the follow-up of 
collagen VI-related myopathies. 
 
The project has been divided into the following steps: 
 
a) Retrotranscription and identification of miRNAs expressed in the serum of 
col6a1-/- and wild type mice by qPCR. 
 
b) Identification of up-regulated and down-regulated miRNA levels 
comparing serum of col6a1-/- and wild type  serum performing statistical 
analyses. 
 
c) Selection of miRNAs significantly dysregulated in order to create a  miRNA 
panel which could be studied in future analyses in serum of patients with 
Bethlem myopathy and Ullrich congenital muscular dystrophy. The 
candidates selection has been made through pathway analyses coupled 
with literature data search. 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.Material and methods 
 
3.1.1 Col6a1 -/- mutant mice 
In order to study the collagen VI function, Bonaldo et al. generated a mouse 
model with inactivation of col6a1 gene using "targeted gene disruption". 
In embryonic stem cells (ES cells) the col6a1 gene has been inactivated using a 
target vector containing a neomycin-resistant cassette included in the second 
exon. 
Heterozygous mice for the mutation have been created by crossing male 
chimeras with C57BL/6 female. 
 
 
 
Southern blot analysis performed on ES cells, showed that the insertion of the 
neo cassette in the second exon interrupted the col6a1 coding sequence blocking 
the translation from amino acid 66 and increasing the DraI fragment (from 5.6 
to 6.8 kb). 
 
 
             
 
 
Imagine 6. Structure of the 5' col6a1 murine gene portion, structure of the construct and 
resulting targeted loci. (Imagine taken from Bonaldo, P.  et al., Collagen VI deficiency 
induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum 
Mol Genet, 1998. 7(13): p. 2135-40.) 
) 
Imagine 7. Southern blot analysis of ES cells. (Imagine taken from Bonaldo, 
P., et al., Collagen VI deficiency induces early onset myopathy in the mouse: an 
animal model for Bethlem myopathy. Hum Mol Genet, 1998. 7(13): p. 2135-
40.) 
Northern blot analysis of total RNA extracted from primary embryonic fibroblasts 
showed how cells -/- did not express α1 (VI) mRNA, while gene expressions of 
α2(VI) and α3(VI) were not affected. 
 
 
 
 
 
 
 
 
 
 
 
 
The lack of the α1 (VI) chain leads to a block of collagen VI synthesis because 
the three chains can not be assembled. 
That has been showed by collagen VI immunofluorescence analysis where it is 
evident an absence of collagen VI staining in the col6a1-/-
 
embryo tissues. 
In addition, histological changes in skeletal muscle of col6a1-/-
 
mice were 
detected. In particular, marked signs of myopathy features as muscle necrosis, 
phagocytosis 
and variation in 
the fibers diameter 
were found.[34] 
 
 
 
 
 
Imagine 8. Northern blot of primary embryonic fibroblasts -/- (Imagine taken 
from Bonaldo, P., et al., Collagen VI deficiency induces early onset myopathy 
in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet, 1998. 
7(13): p. 2135-40.) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2 Mice serum 
Animal models and related procedures have been performed at the Department 
of Molecular Medicine, University of Padova, Padova, Italy. 
Bloods from n=5 col6a1+/+ (WT) of the inbred C57BL/6J strain and n=6   col6a1-
/- (KO) previously backcrossed in the C57BL/6J strain have been collected from 
jugular veins.  
All the mice were 8 months old male.  
The blood has been transferred into a 1.5 ml Eppendorf Safe-Lock Tubes™ and 
allowed to clot for 45' at room temperature, for 15’ on ice and later centrifuged 
at 3000 g x 10' at 4°C. 
Imagine 9. Immunodetection of colVI. (a and b) sections 
of 16 days old WT +/+ and col6a1-/- mice thoracic wall 
and fibroblasts (c and d) stained with rabbit IgG against 
mouse collagen VI. The same fibroblasts stained with 
antibody against fibronectin  (anti-FN). (Imagine taken 
from Bonaldo, P., et al., Collagen VI deficiency induces 
early onset myopathy in the mouse: an animal model for 
Bethlem myopathy. Hum Mol Genet, 1998. 7(13): p. 2135-
40.) 
 
 
Imagine 10. (Top-Left) Longitudinal section of 40 days old col6a1-/- quadriceps muscle 
shows necrosis and macrophage infiltration of a muscle fiber and 4 months old col6a1-/- 
quadriceps (Top-right) shows fibers with central nuclei. (Imagine taken from Bonaldo, P., et 
al., Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for 
Bethlem myopathy. Hum Mol Genet, 1998. 7(13): p. 2135-40.) 
 
 
Finally the supernatant was collected, transferred in a 1,5 ml Eppendorf Safe-
Lock Tubes™ and frozen at -80°C. 
 
3.2 miRNA Isolation 
RNA degradation issue has been removed working in an RNA free environment 
using RNaseZap® RNase decontamination solution (Life Technologies) to clean 
workspace. 
Small RNA (<1000 bp) isolation has been performed using miRCURY ™ RNA 
Isolation Kit (Exiqon) using the following protocol:  
 After thawing, samples have been centrifuged at 3000 g x 5 min to pellet 
any debris and insoluble components. 
 For rodent samples 50 µL of serum topped up with 200 µL of RNase free 
water were used. 
 200 µL supernatant from previous step to new tube were transferred and 
60 µL of Lysis solution (BF) added, vortexed for 5 sec and incubated for 3 
min at room temperature. For downstream PCR analysis, 1 µL RNA-Spike-
in template mixture was added. 
 20 µL of Protein Precipitation Solution BF were added, vortexed for 5 sec 
and incubated for 1 min at room temperature. Centrifuged for 3 min at 
11000 x g. 
 the clear supernatant was transferred into a new collection tube (2mL, 
with lid) 
 270 µL Isopropanol were added and vortexed 5 sec. 
 a microRNA Mini Spin Column BF was placed in a collection tube and 
sample was loaded onto the column, incubated for 2 min at room 
temperature, centrifuged for 30 sec at 11000 x g. the flow was discarded 
through and a column was placed back into the collection tube. 
 100 µL Wash Solution BF was added to the microRNA spin column BF, 
centrifuged for 30 sec at 11000 x g, the flow-through was discarded and 
the column was placed back into the collection tube. 
 700 µL Wash Solution 2 BF were added to the microRNA spin column BF, 
centrifuged for 30 sec at 11000 x g. The flow-through was discarded and 
the column was placed back into the collection tube. 
 250 µL Wash Solution 2 BF were added to the microRNA spin column BF. 
Centrifuged for 2 min at 11000 x g to dry the membrane completely. 
 The microRNA spin column BF was placed in a new collection tube (1,5 
mL), 50 µL of RNase free water were added directly onto the membrane 
of the microRNA spin column BF. 
 The microRNA spin column BF was incubatee for 1 min at room 
temperature and centrifuged for 1 min at 11000 x g. 
 The purified RNA sample was stored at -20° C for a few days or a -70°C 
for a long term storage. 
 
3.3 microRNA profiling 
Once extracted, the microRNAs from the col6a+/+ and col6a1-/-
 
mice serum,  the 
samples were reverse transcribed (RT) and the relative gene expression was 
assessed by quantitative real-time PCR using SYBR® Green, using the miRCURY 
LNA™ Universal RT microRNA PCR system package (Exiqon).   
The kit contains four types of reagent kits: 
 Universal cDNA synthesis kit II 
 ExiLENT SYBR® Green master mix kit 
 PCR Mouse&Rat panels including the microRNA primer sets (384 wells) 
 RNA Spike-in kit  
 
 
3.4 Reverse transcription 
Reverse transcription reaction (RT) gave rise to a cDNA template.  
During the process, a poly-a tail was added to the mature miRNA and a specific 
primer with a 5' universal tag was used for the synthesis. 
 
  
  
 
The reverse transcription was performed using the Universal cDNA synthesis kit 
II and the following protocol: 
 
 The required amount of RT working solution was prepared and placed on 
ice. For each sample the required mix for 2 x 384 wells plate was 
composed by:  
 
Reagent (Panel I+II) Volume (µL) 
5x Reaction buffer 8,5 
Nuclease-free water 18,5 
Enzyme-reverse transcriptase 4,5 
Synthetic RNA spike ins 2,5 
Template total RNA (5ng/µL) 8,5 
Total volume 42,5 
 
 
  RT working solution was dispensed into nuclease free tubes. 
 Template RNA was dispensed in each tube. 
 The reaction was mixed by very gentle vortexing or pipetting to ensure 
that all reagents were thoroughly mixed. After mixing,the samples were 
spinned down. 
 The samples were incubated for 60 min at 42°C. 
Imagine 11. Rt-process outline (imagine 
taken from http://n www.exiqon.com 
/ls/PublishingImages/Figures/miRNA-qPCR-
overview.gif) 
 The reverse transcriptase was heat-inactivated for 5 min at 95°C.  
 Immediately cooled to 4°C. 
 Stored at 4°C or freeze. 
 
 
3.5 Real-Time PCR 
The miRNA levels in mice serum was quantified by quantitative Real-Time 
polymerase chain reaction (qPCR), a technique based on the principle of a 
standard PCR in which a DNA exponential amplification occurs. 
In qPCR this process is coupled to the DNA quantification thanks to SYBR® 
Green, a fluorescent reporter, added in the PCR mix. 
SYBR® Green is a cyanine dyes that binds double stranded DNA.  
When the amplification reaction is complete, the resulting SYBR® Green-DNA 
double helix complex increases the emitted fluorescence detected by Applied 
Biosystems 7900HT Fast Real-Time PCR System. 
DNA amplification occurs through numerous cycles wherein each one is 
characterized by three phases: 
 
 Denaturation phase: the DNA is incubated at high temperatures in order 
to allow the opening of the double helix. 
 Annealing phase: the link between primers and complementary sequences 
occurs at a specific temperature 
 Extension phase: a complementary strand to the DNA template is 
synthesized by the taq polymerase enzyme. 
 Plateau phase: when there is no longer exponential amplification after a 
certain number of cycles in qPCR quantification of transcript occurs 
precisely during the exponential phase of amplification. 
 
Several cycles of amplification are required because a given amount of product is 
detected. 
At the end of the process the Applied Biosystems 7900HT Fast Real-Time PCR 
System SDS software v2.3 plotted a diagram that compared the emitted 
fluorescence values vs threshold cycles (Ct). 
Ct (or Cq, quantification cycle) represents the point where the amount of 
fluorescence begins to increase rapidly because the exponential DNA duplication. 
The threshold level is the point in which the fluorescence is significant from 
background fluorescence. 
 
 
 
 
The qPCR reactions were performed using the following protocol: 
 
 The plates were spinned down in a centrifuge. 
 Water, ExiLENT SYBR® Green master mix and ROX (Life technologies) 
reference dye were combined in order to normalize the fluorescent signal: 
2000 μL 2x master mix and 1980 μL water and 80 μL ROX. 
 The sample was mixed gently and spinned down. 
 42 µL cDNA (panel I+II) were added and mixed. 
 10 µL PCR Master mix were added: cDNA mixed to each well. 
 The plates were sealed with optical sealing and spinned briefly. 
 The used cycled conditions were: 
a)95° x 10 min. 
b)40 amplification cycles: 95˚C x 10 s, 60˚C x 1 min. 
Imagine 12. qPCR plot (Imagine taken from http-
//www.thermoscientificbio.com/applications/pcr-and-qpcr/introduction-to-
qpcr/.jpg) 
 The Applied Biosystems 7900HT instrument Fast Real-Time PCR System was 
used for the analysis. 
This instrument is equipped with an argon ion laser which sends light to each 
well of the plate in order to excite the SYBR® Green that emits light (λ=520 
nm). 
This process occurs every 8-10 seconds and the signal from each individual well 
is detected from the room and sent to the SDS software. 
 
 
 
 
3.6 Locked Nucleic Acid (LNA™) 
The primers used are miRNA specific and optimized with LNA ™ (locked nucleic 
acid). 
LNAs are a class of nucleic acids characterized by a specific structure in which 
the ribose ring is locked by a methylene bridge that creates a link between 2'-4'-
O atom and the C atom. 
When the LNA are incorporated into the primer, its link with the complementary 
DNA is faster and is more stable. 
An improved affinity is confirmed by an increase in duplex melting temperatures 
(Tm) of about 10 ° C for each base.[35] 
 
3.7 Quality controls and inter-plate calibration 
Imagine 13. Applied Biosystems 7900HT 
(imaginehttp://cgs.hku.hk/portal/files/CGS/Geno
mics/Realtime-PCR/7900ht_hardware.jpg) 
In order to check the quality of the miRNAs isolation and cDNA synthesis 
processes some synthetic RNA spike-ins were added to the samples before RT 
and qPCR processes. 
This additional step is essential because the RNA may have been degraded due 
to nucleases, or its quality may not be good because the presence of 
contaminants. 
Specific spike-ins were also added to check the cDNA synthesis efficiency and 
the quality of its replication during the qPCR process. 
Although the Applied Biosystems 7900HT Fast Real-Time PCR System is very 
reliable in terms of reproducibility, sometimes there may be some differences in 
the signal amplification for run-to-run since it is not possible to run more than 
one plate at a time. 
In order to avoid these differences, an inter-plate calibration was performed 
using a specific inter-plate calibrator (IPC), which is a synthetic RNA that was 
added in triplicate to each plate and after qPCR analysis it must show to have a 
constant expression in col6a1-/- mice serum. 
This has allowed a correction of the Ct, minimizing any inter-plate variations. 
All the synthetic miRNA oligonucleotides and inter-plate calibrators were included 
in the RNA spike-in kit for quality control of the RNA isolation and cDNA 
synthesis steps of a miRCURY LNA™ Universal RT microRNA PCR (EXIQON). 
An efficient serum profiling study requires also that red and white blood cells 
present membrane integrity and consequently no lysis during samples 
preparation or storage processing are allowed (in this case all the samples were 
stored at -80°C). 
Given this, before proceeding to the profiling step, the hemolysis test for each 
sample was performed in accordance with the miRCURY ™ RNA Isolation Kit 
(Exiqon) protocol as described in results session. 
 
 
3.8 Normalization of qPCR values 
After obtaining the miRNAs expression values and made all the quality controls 
and the inter-plate calibration in order to minimize variations between Ct, data 
normalization was performed. 
In general there are two strategies to normalize the qPCR data:  
1) to identify a stable expressed miRNAs in serum that could be used as 
reference genes or, 2) the “global mean value normalization methods” described 
by Mestagh et al.[61]  
In the Mestagh’s method the global mean value of all the expressed microRNAs 
of each sample is used instead of the reference gene. 
For both miRNA selection and normalization the following steps were 
undertaken: 
 Exclusion of all miRNAs with undetermined value or Ct values >35 from 
the data analysis. 
 Calculation of Ct global mean value (CtG) of all miRNAs expressed in each 
sample. 
 Determination of ΔCt using the formula: ΔCt=ΔCtmiRNA–ΔCtG 
 Identification of Fold Changes (FC) in col6a1-/- and WT mice serum using 
the formula FC=2-ΔΔCt 
All the above described analysis were performed using the spreadsheet 
application Microsoft Excel 2013. 
 
 
3.9 Statistical analysis  
In order to select the ideal test to perform for the comparison of serum levels of 
expressed miRNAs between KO and WT mice, first a normality test to see the 
data distribution (KO and WT) was performed. 
The Kolmogorov-Smirnov test (KS test) was used and it showed that the values 
were not normally distributed. 
Statistic Mann-Whitney U test was then used to compare the obtained data. 
The above mentioned test is considered the non-parametric counterpart of the t-
test for two independent samples and it is also called Wilcoxon rank sum test. 
All the analysis were performed using the SPSS software and all P-values> 0.05 
were considered significant. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.Results 
 
4.1 Hemolysis test of the samples 
The level of a microRNA highly expressed in red blood cells (hsa-miR-451a) was 
compared with a specific microRNA unaffected by hemolysis (hsa-miR-23a-3p) 
using the following formula: 
 delta Ct hemolysis Value=Ct miR-23a-3p -Ct miR-451 
where values >5 are an indicator of hemolytic contamination. 
In the KO and WT serum samples used for this project all the delta Ct hemolysis 
values were under 5 showing that samples have not been affected by 
erythrocyte microRNA contamination. 
 
 
 
  
 
 
 
 
 
4.2 Mice serum miRNA expression  
In order to identify differentially expressed miRNAs in col6a1-/- (KO) and wild-
type (WT) mice serum, miRNA expression profiles analysis by SYBR Green-based 
real-time PCR of n=752 miRNAs in n=11 mice (n=5 WT, n=6 Col6a1-/-) was 
performed.  
Imagine 14-15. Comparison of mmu-miR-23a-3p 
and mmu-miR-451a Ct values of KO and WT mice 
serum. A.Line graphs shows the Ct levels of  red 
blood cells highly Expressed mmu-miR-451a (red) 
and the control mmu-miR-23a-3p unaffected by 
hemolysis and bar graph shows a delta Ct hemolysis 
Value < 0.05 for each mice serum sample. 
Among the col6a1-/- mice group, n=4 were eight months old and n=2 were seven 
months old while all n=5 WT mice were 8 months old. 
Serum miRNA levels were compared using Mann-Whitney U test and a    P-value 
<0,05 was consider statistically significant. 
After qPCR analyses, a total of n=333 miRNA serum levels were used for 
statistical comparisons while n=419 miRNAs were excluded because the lack of 
amplification or very low expression (Ct>35) in mice serum. 
N=42 serum miRNA levels resulted significantly dysregulated after statistical 
analysis (P<0.05) performed in n=5 WT and n=6 KO (comparing both seven and 
eight months old KO mice vs WT) suggesting that expression of many miRNAs is 
altered in BM and UCMD.  
The same statistical analysis was performed excluding n=2 col6a1-/- seven 
months old mice from the KO group in order to find any changes in miRNAs 
expression levels due to the activation of different signalling pathways in a age-
dependent fashion. 
Results showed that there were significant differences in serum miRNA 
expression between seven and eight months old mice. 
In col6a1-/- 8 old months mice serum, n=32 miRNAs were significantly 
dysregulated, among them n=23 dysregulated miRNAs were shared with the 
miRNAs dysregulated in the entire group (including seven and eight months old 
mice together). 
 
  
 
 
 
 
Imagine 16. Pie chart showing that several miRNAs were undetected in mice serum (both 
WT and KO).B Bar graph highlight that 42 miRNAs are significantly dysregulated in 7+8 
months old Col6a1-/- mice serum vs. WT (P<0,05) and 32 in 8 months old Col6a1-/- mice 
serum vs. WT (P<0,05). Several (22) dysregulated miRNAs of 8 months old Col6a1-/- 
mice are common with the miRNAs significantly dysregulated in grouped analysis (7+8 
months)  
 
  
 
 
 
4.3 Dysregulated miRNAs expression levels 
Imagine 17. List of the dysregulated miRNAs in 7 and 8 months old mice. 
 
In order to better understand whether the miRNAs were significantly down or 
over-expressed in col6a1-/- mice serum, heat maps using the free clustering 
software Gene Cluster [36] were performed. 
In these analysis rows represent dysregulated miRNAs and columns represent 
samples (KO and WT mice). 
Fold changes (FC), calculated using a log2 scale (-∆∆Ct) were included in the 
maps where red colour represents overexpressed miRNAs and green colour 
represents miRNAs with lower expression. 
Moreover, differential heat maps were performed including and excluding seven 
old months col6a1-/- mice serum from the KO group and finally and heat map 
with common dysregulated miRNAs levels was designed. 
 
 
 
 
 
 
 
 
 
 
Imagine 18. miRNA signature in Col6a1-/- (n=6) and in WT (n=5) mice serum.  
Imagine 19. miRNA signature in Col6a1-/- (n=4) and in WT (n=5) mice serum but not in col6a1-/- 
seven months old col6a1-/- mice serum. 
  
 
 
4.4 Dysregulated miRNAs in col6a1-/- vs. WT mice serum 
Heat maps showed that there were n=9 up-regulated miRNAs in col6a1-/- mice 
serum (mmu-miR-26a-5p, mmu-let-7c-5p, mmu-miR-376a-3p, mmu-let-7b-5p, 
mmu-miR-125a-5p, rno-let-7f-1-3p, mmu-miR-30a-3p, mmu-miR-30c-5p, 
mmu-miR-872-3p), among them n=2 (mmu-miR-30c-5p, mmu-miR-872-3p) 
were only slightly up-regulated based on the FC values, and  n=5 down-
regulated miRNA (mmu-miR-183-5p, mmu-let-7f-2-3p, mmu-miR-1983, mmu-
miR-676-5p, mmu-miR-101a-5p) and n=5 slightly down-regulated miRNAs (rno-
miR-223-3p, mmu-miR-503-5p, mmu-miR-744-5p, mmu-miR-29b-3p and mmu-
miR-467d-3p). 
 
 
 
 
 
 
Imagine 20. Heat map of common dysregulated miRNA in both groups (including and excluding 
seven months old col6a1-/- mice serum) 
  
 
                                                   
 
 
 
4.5 Dysregulated miRNAs in col6a1-/- 8 months old vs. WT mice 
serum 
As already mentioned, in order to find any changes in miRNAs expression serum 
levels between seven and eight months old mice, a specific analysis excluding 
seven months old col6a1-/- mice serum from the KO group was performed. 
In this case the heat map showed that n=3 miRNAs were up-regulated (mmu-
miR-154-5p, mmu-miR-382-5p, rno-miR-667-3p), n=1 was slightly up-regulated 
Imagine 21. Upregulated serum miRNA levels in col6a1-/- (n=6) vs. WT (n=5) mice serum. Data 
are presented as a Fold changes (FC) using a log 2 scale (-∆∆Ct). All P-Values are <0.05 (Mann-
Whitney U test)   
 
(mmu-miR-674-3p) and n=5 (mmu-miR-326-3p, mmu-miR-339-5p, mmu-miR-
365-3p, mmu-miR-32-5p, mmu-miR-511-5p) were slightly down regulated in KO 
mice serum in comparison with WT. 
 
 
 
                                    
 
 
 
 
4.6 Common dysregulated miRNAs 
The levels of n=23 miRNAs were found to be significantly dysregulated in serum 
of both the 8-month-old and the 7-month-old KO mice compared to WT animals. 
Namely, n=2 miRNAs (mmu-miR-7a-5p, mmu-miR-195a-5p) were up- 
regulated, n=3 were down regulated (mmu-miR-363-3p, mmu-miR-192-3p and 
mmu-miR-15a-3p) and n=18  were slightly down-regulated (mmu-miR-22-3p, 
mmu-miR-130b-3p, mmu-miR-192-5p, mmu-miR-362-3p, mmu-miR-19a-3p, 
mmu-miR-425-3p, mmu-miR-29a-3p, mmu-miR-210-3p, mmu-miR-215-5p, 
mmu-miR-142-5p, mmu-miR-191-3p, mmu-miR-466g, mmu-miR-130a-3p, 
Imagine 22. Upregulated serum miRNA levels  in Col6a1-/- 8 months old(n=4) vs. WT (n=5) mice 
serum but not in Col6a1-/- seven months old col6a1-/-mice serum. Data are presented as a Fold 
changes (FC) using a log 2 scale (-∆∆Ct). All P-Values are <0.05 (Mann-Whitney U test)   
 
mmu-miR-322-5p, mmu-miR-423-3p, mmu-miR-297a-5p, mmu-miR-19b-3p 
and mmu-miR-221-3p) in KO serum. 
 
 
 
 
4.7 Pathway Analysis 
miRNAs are post-transcriptional regulators that act by binding the mRNA and 
influenced its gene expression. The prediction of the target mRNAs which could 
be regulated by miRNA changes is highly important. 
The hypothesis was that increasing levels of serum miRNAs could exert an 
inhibitory effect on the target related mRNA.  
Therefore, a pathway analysis was carried out using the online tool Diana 
mirpath v2.0 [37], a software that creates associations between miRNAs and 
target genes. Once that the target genes has been identified, it could help 
defining signalling pathways altered in the disease progression. 
Hierarchical clustering on both miRNAs and pathways were calculated using 
squared Euclidean distances in order to highlight miRNA-miRNA and miRNA-
pathways relationship obtained from miRBase [38]and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) [39] respectively. 
P-values were calculated using the one-tailed Fisher’s exact test and  
KEGG pathways with p-values <0.05 were considered significant. 
 
Imagine 23. Common miRNAs upregolated levels in Col6a1-/- mice serum. Data are presented as 
a Fold changes (FC) using a log 2 scale (-∆∆Ct). All P-Values are <0.05 (Mann-Whitney U test).   
 
 
Imagine 24. Up regulated miRNAs in col6a1-/-  mice serum vs pathways heat map.Lower 
significance values are represented by darker coluors. (Map generated from 
http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=site/index)  
 
Pathways analyses showed that n=4 overexpressed miRNAs in col6a1-/- mice 
serum (mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-7c-5p and mmu-let-7b-
5p) could potentially regulate genes involved in signalling pathways critical for 
the development, efficiency and homeostasis of the skeletal muscle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7.1 MAPK signaling pathway 
The MAPK signaling pathway regulates an intracellular proteins system that can 
be activated mainly by hormones, growth factors and environmental stress. 
Once activated, the MAPK proteins induce phosphorylation of cytoplasmic and 
nuclear proteins.[40] 
The MAPK family consists of four known subfamily-proteins: extracellular signal-
regulated kinase 1/2 (ERK 1/2), c-Jun NH2 terminal kinase (JNK), p38 and ERK5. 
These proteins are activated by the phosphorylation of threonine and tyrosine 
residues by MAP kinase kinases and are inactivated by phosphatases.[41] 
 
 
 
 
 
 
Imagine 25. MAPK signalling pathway KEGG (imagine  taken from http://www.genome.jp/kegg-
bin/show_pathway?mmu04010)  
  
 
 
 
4.7.2 PI3K/Akt signaling pathway 
Phosphatidyinositol the 3'-kinase (PI3K) Akt signaling pathway regulates 
important cellular functions such as transcription, proteins translation, cellular 
growth and proliferation. 
Akt (also known as "protein kinase B," PKB) is the main protein having a key 
role in this pathway; this protein could be activate by PI3K and could translocate 
to the plasma membrane where it is finally completely activated by PDK1 and 
PDK2 kinases.[42] 
 
 
miRNA Target gene
mmu-miR-26a-5p Mef2c
mmu-miR-26a-5p Taok1
mmu-miR-26a-5p Map2k4
mmu-miR-26a-5p Mapk9
mmu-miR-26a-5p Sos1
mmu-miR-26a-5p Gng12
mmu-miR-26a-5p Chp1
mmu-miR-26a-5p Ppp3r1
mmu-miR-26a-5p Pla2g4c
mmu-miR-26a-5p Tab2
mmu-let-7b-5p Dusp6
mmu-let-7b-5p Map4k3
mmu-let-7b-5p Nlk
mmu-let-7b-5p Tgfbr1
mmu-let-7b-5p Akt1
mmu-let-7b-5p Braf
mmu-let-7b-5p Nras
mmu-let-7b-5p Crk
mmu-let-7b-5p Flna
mmu-let-7b-5p Ppp3r1
mmu-let-7b-5p Ikbkg
mmu-let-7b-5p Dusp1
mmu-let-7b-5p Mapk1
mmu-let-7c-5p Mapk1
MAPK signaling pathway 
Imagine 26. Genes belonging to MAPK signalling 
pathway targeted by mmu-miR-26a-5p, mmu-let-
7b-5p and mmu-let-7c-5p 
  
 
 
 
 
 
 
4.7.3 ERBb signaling pathway  
The ErbB signaling pathway is composed by four tyrosine kinases receptors: 
EGFR/ErbB1/Her1, ErbB2/NEU/HER2, ErbB3/HER3 and ErbB4/HER4. All of them 
present highly homology with erythroblastic leukemia viral oncogene. 
This signalling pathway plays an important role in the regulation of cell 
proliferation, apoptosis and differentiation. 
miRNA Target gene
mmu-miR-195-5p Ccnd1
mmu-miR-195-5p Cdk6
PI3K/Akt signaling pathway 
Imagine 27. PI3K/AKT signaling pathway KEGG (imagine  taken from 
http://www.genome.jp/kegg-
bin/show_pathway?org_name=mmu&mapno=04151&mapscale=&show_description=hide)  
Imagine 28. Genes belonging to PI3K/AKT 
signaling pathway targeted by mmu-miR-195-5p. 
  
 
 
 
 
 
 
 
 
miRNA Target gene
mmu-miR-26a-5p Pik3r3
mmu-miR-26a-5p Map2k4
mmu-miR-26a-5p Mapk9
mmu-miR-26a-5p Sos1
mmu-miR-26a-5p Shc4
mmu-let-7c-5p Myc
mmu-let-7c-5p Crk
mmu-let-7b-5p Akt1
mmu-let-7b-5p Braf
mmu-let-7b-5p Nras
mmu-let-7b-5p Crk
ErbB signaling pathway 
Imagine 24. ErbB  signaling pathway KEGG (imagine  taken from http://www.genome.jp/kegg-
bin/show_pathway?org_name=mmu&mapno=04012&mapscale=&show_description=hide)  
Imagine 29. Genes belonging to ErbB signaling 
pathway targeted by mmu-miR-26a-5p, mmu-let-
7b-5p and mmu-let-7c-5p. 
 
4.7.4 mTOR signaling pathway 
The mammalian target of rapamycin (mTOR) acts as regulator of metabolism, 
growth and cell proliferation. 
This pathway is composed by the mTOR protein complex 1 (mTORC1) and mTOR 
protein complex 2 (mTORC2).[43] 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA Target gene
mmu-miR-26a-5p Ulk1
mmu-miR-26a-5p Pik3r3
mmu-miR-26a-5p Ddit4
mmu-miR-26a-5p Rragc
mTOR signaling pathway 
Imagine 30. mTOR  signaling pathway KEGG (imagine  taken from  http://www.genome.jp/kegg-
bin/show_pathway?mmu04150)  
Imagine 31. Genes belonging to mTOR  signaling 
pathway targeted by mmu-miR-26a-5p. 
 
4.7.5 Focal Adhesion signaling pathway 
Focal adhesions are structures composed by actin filaments that allow their 
binding to transmembrane receptors. 
The components of focal adhesions link the actin cytoskeleton to the cell 
membrane and also act as signalling molecules.[44] 
 
 
 
 
 
 
 
miRNA Target gene
mmu-let-7b-5p Vav3
mmu-let-7b-5p Thbs1
mmu-let-7b-5p Akt1
mmu-let-7b-5p Braf
mmu-let-7b-5p Ccnd1
mmu-let-7b-5p Igf1r
mmu-let-7b-5p Rock2
mmu-let-7b-5p Crk
mmu-let-7b-5p Itga4
mmu-let-7b-5p Flna
mmu-let-7b-5p Actg1
mmu-let-7b-5p Col4a2
Focal adhesion signaling pathway 
Imagine 32. Focal Adhesion signaling pathway KEGG (imagine  taken from 
http://www.genome.jp/kegg/pathway/hsa/hsa04510.html)  
Imagine 33. Genes belonging to mTOR  signaling 
pathway targeted by mmu-let-7b-5p. 
 
4.7.6 Actin Cytoskeleton signaling pathway  
Actin cytoskeleton is a dense network formed by polymers of actin and other 
proteins associated with them. 
This cellular element is especially important for cell motility and it is responsible 
for cell shape changings during the cell cycle.[45] 
 
 
 
 
 
 
 
miRNA Target gene
mmu-let-7b-5p Vav3
mmu-let-7b-5p Braf
mmu-let-7b-5p Rdx
mmu-let-7b-5p Nras
mmu-let-7b-5p Rock2
mmu-let-7b-5p Crk
mmu-let-7b-5p Itga4
mmu-let-7b-5p Actg1
mmu-let-7b-5p Ssh1
Regulation of actin cytoskeleton signaling pathway 
Imagine 34. Actin cytoskeleton  signaling pathway KEGG (imagine  taken from  
http://www.genome.jp/kegg-
bin/show_pathway?org_name=mmu&mapno=04810&mapscale=&show_description=hide)  
Imagine 35. Genes belonging to actin cytoskeleton  signaling 
pathway targeted by mmu-let-7b-5p. 
 
4.7.7 Calcium signaling pathway  
Ca2+ is an essential ion for the proper functioning of skeletal muscle cells, in 
particular allows the cell to contract and also acts as a second messenger. 
The concentration of intracellular Ca2+ should be perfectly regulated, because 
the reserves of Ca2+ are stored in the endoplasmic reticulum. [46] 
 
 
 
 
 
  
4.7.8 ECM-receptors signaling pathway  
miRNA Target gene
mmu-let-7b-5p Slc25a4
mmu-let-7b-5p Stim1
mmu-let-7b-5p Gnal
mmu-let-7b-5p Atp2a2
mmu-let-7b-5p Atp2b2
mmu-let-7b-5p Slc8a2
mmu-let-7b-5p Ppp3r1
Calcium signaling pathway
Imagine 36. Actin cytoskeleton  signaling pathway KEGG (imagine  taken from  
http://www.genome.jp/kegg-
bin/show_pathway?org_name=mmu&mapno=04020&mapscale=&show_description=hide)  
Imagine 37. Genes belonging to Calcium  
signaling pathway targeted by mmu-let-7b-5p. 
 
The extracellular matrix (ECM), mainly composed of glycoproteins, collagen 
fibrils and proteoglycans, have a structural role and it is also involved in the 
modulation of many cellular pathways. 
Extracellular matrix is in contact with the muscle cell membrane through various 
proteins, such as integrins. 
By these interactions the ECM can act as a regulator of adhesion, differentiation 
and cell proliferation.[47] 
 
 
 
 
 
 
 
 
5.Discussion 
miRNA Target gene
mmu-miR-26a-5p Itgb1
ECM-receptor signaling pathway
Imagine 38. ECM-receptor signaling pathway KEGG (imagine  taken from  
http://www.genome.jp/kegg-
bin/show_pathway?org_name=mmu&mapno=04512&mapscale=&show_description=hide)  
Imagine 39. Genes belonging to ECM-receptor 
signaling pathway targeted by mmu-miR-26a-5p. 
 
 Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are 
a subtype of congenital muscular dystrophies (CMDs) caused by mutations in the 
genes coding for the collagen VI main chains (COL6A1, COL6A2 and COL6A3). 
Collagen VI is a ubiquitous extracellular matrix (ECM) protein synthesized by 
fibroblasts and skeletal muscle cells having both structural and signalling 
functions [10]. 
By the interaction with other ECM proteins such as integrins, decorin, biglican, 
fibronectin and basal lamina type IV collagen [21, 22], collagen VI represents a 
bridge between muscle cells and surrounding ECM, playing an important 
signalling role [1]. 
UCMD and BM diagnosis requires muscle biopsy, which is an invasive test that 
allows to study the fibers morphology and  
allows the identification of the characteristic histological features observed in 
collagenopaties [4]. 
The purpose of this project was to study the serum expression patterns of a 
large group of miRNAs by quantitative Real-Time polymerase chain reaction 
(qPCR) in collagen VI−deficient mice (col6a1-/-) [34] in order to find 
dysregulated miRNAs which could be useful in future as no invasive biomarker 
for the diagnosis and the follow-up of UCMD and BM patients. 
Col6a1-/- mouse is considered the ideal animal model to study the collagen VI-
related myopathy since muscle histophatology shows marked signs of myopathy 
like muscle necrosis and regenerating fibers [34]. 
MiRNAs are non-coding RNAs (ncRNAs) long 22 nucleotides that act as post 
transcriptional inhibitors binding RNA targets and inhibiting their expression; 
these oligonucleotides are easily detectable in different body tissues.[30] 
Recent studies showed that miR-1/206 and miR-133a/ 133b family members are 
specifically expressed in skeletal and cardiac muscle.[31] 
This project identified 333 miRNA expressed in col6a1-/- mice serum and showed 
that 6,5% of them were significantly differentially expressed between Col6a1-/- 
and WT mice serum. 
A total of 51 miRNAs were significantly dysregulated; 17/51 miRNAs resulted up-
regulated and 34/51 down-regulated.  
Pathway analyses coupled to research literature findings were performed in 
order to identify the most significant dysregulated miRNAs which could be used 
as candidates for further proof-analysis in human serum. 
The performed pathway analysis were based on overexpressed miRNA because 
our hypothesis was that the characteristic inhibitory effect of each miRNA may 
increase in relation to its serum amount, however literature research was used 
also to find correlation between down-regulated miRNAs and other CMDs forms. 
Pathway analysis associates miRNA to the relatives target genes and are based 
on previous studies or made by a specific algorithm that create miRNA-target 
associations (analysing the miRNA-target sequence homology) and including the 
target genes involvement in a specific signalling-pathway. 
Interestingly, we have identified 4 significantly up-regulated miRNAs in col6a1-/- 
mice serum  (mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-7c-5p and mmu-
let-7b-5p) that potentially could bind transcripts of genes involved in crucial 
pathway for skeletal muscle cells development, differentiation or coding for ECM 
proteins. 
Mmu-let-7c-5p and mmu-let-7b-5p bind mitogen-activated protein kinase 1 
(Mapk1) and mmu-let-7b-5p bind mitogen  binds Mitogen-Activated Protein 
Kinase 4 (Map4k3) gene, belonging to the MAPK signaling pathway which is 
activated in human skeletal muscle during exercise. [40] 
Grendinger and colleagues found that MAPK signalling pathway activation 
controls the C2 muscle cell lines differentiation increasing Myo-D family proteins 
(Myf5 and Myo-D) levels [48] while Burks and collaborators suggested that 
MAPKs (a Transforming growth factor beta TGF-β protein members) plays an 
important role in skeletal muscle pathogenesis and they are involved in several 
inherited neuromuscular disorders [49]. 
Moreover mmu-let-7c-5p and mmu-let-7b-5p bind the insulin-like growth factor 
1 gene (Igf1) a PIK3/Akt pathway activator. 
Glass and colleagues suggested that activation of PIK3/Akt pathway results in 
myostatin inhibition and atrophy mediators MuRF1 and MAFbx (atrogin1) up-
regulation in skeletal muscle [50].   
Previous studies showed that IGF-1 expression lead to muscle mass and 
strength increase by promoting  the regeneration [51-55] and that IGF-1 
reduced fibrosis in mdx mice. [56] 
In this context, an overexpression of both, mmu-let-7c-5p and mmu-let-7b-5p 
could reduce the skeletal muscle cells differentiation acting to MAPK signaling 
pathway and exert inhibitory effect reducing the IGF-1 activity in col6a1-/- mice. 
An excess of mmu-let-7b-5p may also exert adverse effects on the muscle 
contraction linking the Stromal Interaction Molecule 1 
gene (Stim1) a gene encoding for a endoplasmic reticulum calcium receptor 
whose malfunction caused by mutations was associated to aggregates tubular 
myopathy form.[46] 
In addition to this effect, mmu-let-7b-5p could modify the ECM composition and 
cytoskeleton organization by the interaction with several proteins belonging to 
these structures.  
Among the potential target genes of mmu-miR-26a-5p I have identified as 
interested candidate the integrin β1 (Itgβ1) gene.  
It has been shown that β1 integrin is important for NMJ (neuromuscular 
junction) development in skeletal muscle and lack of this receptor is linked to an 
interruption of the connection between skeletal muscle and motor neurons. [57] 
β1 integrin are also involved in signalling connecting skeletal muscle to the 
surrounding ECM. [58] 
Pathway analysis highlighted a link between mmu-miR-26a-5p and several 
mTOR signalling pathway genes which often lower expression levels associated 
with myopathy conditions.  
Interestingly, Risson and colleagues found that mTOR- mouse had lower levels of  
dystrophin and related Dystrophin-Glycoprotein Complex (DGCs); this 
observations have been linked to uthrophin overexpression as observed in mdx 
mice.[43] 
The mmu-miR-26a-5p could have then negative effects on the NMJ formations 
and promoting the dystrophic phenotype development and progression by mTOR 
signalling alterations. 
This work has also shown that mmu-miR-29b-3p and mmu-miR-29a-3p were 
significantly down-regulated in of Col6a1-/- mice serum.  
Wang and colleagues found that in myoblast cells loss of miR-29 contributes to 
dystrophic changes in DMD muscles and its down regulation has been identified 
in mdx mice serum.[59] 
This study clearly indicated that several miRNAs are significantly dysregulated in 
Col6a1-/- mice serum compared to WT and among them mmu-miR-195a-5p, 
mmu-miR-26a-5p, mmu-let-7c-5p and mmu-let-7b-5p could potentially bind 
transcripts of genes involved in important signalling pathways for development 
and differentiation of skeletal muscle cells. 
Their serum upregulation may have effects on the protein regulation resulting in 
a molecular pathways alteration with the consequent histological changes 
observed in muscles of collagen VI−deficient mice. 
Nevertheless, further functional studies using miRNA mimics and inhibitors in cell 
cultures from the same Col6a1-/- mice are essential in order to confirm the above 
described hypothesis. 
A study of Col6a1-/- mice muscle miRNA levels will also be useful to verify if 
candidate miRNA expression patterns are different between serum and muscle of 
Col6a1-/- mice, as demonstrated in mdx mouse by Roberts and colleagues.[60] 
Finally, the results obtained in this study have to been considered preliminary 
data and they could be potentially used in order to select a miRNA panel that 
could be tested on serum of affected patients.  
Serum levels of the dysregulated miRNAs identified in this study (upregulated 
;mmu-miR-195a-5p, mmu-miR-26a-5p, mmu-let-7c-5p and mmu-let-7b-5p and 
downregulated:mmu-miR-29b-3p and mmu-miR-29a-3p) will be analysed 
performing qPCR in a large cohort of BM and UCMD patients.  
If a panel of dysregulated miRNAs will be identified, this will be an extremely 
powerful tool that may allow to skip the painful and invasive muscle biopsy 
procedure. 
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